Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

JAMA

Volumn 283, Issue 4, 2000, Pages 485-491

  Schairer, Catherine ^a   Lubin, Jay ^a   Troisi, Rebecca ^a,b   Sturgeon, Susan ^a,c   Brinton, Louise ^a   Hoover, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER RISK; DRUG MIXTURE; FEMALE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0034716353     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.4.485     Document Type: Article

References (15)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet. 1997;350:1047-1059.
2. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 1994;5:491-500.
3. Breslow NE, Day NE. Statistical Methods in Cancer Research: The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987.
4. Preston DL, Lubin JH, Pierce DA, McConney ME. EPICURE [software]. Release 2.0. Seattle, Wash: HiroSoft International Corp; 1996.
5. Baker LH. Breast Cancer Detection Demonstration Project. CA Cancer J Clin. 1982;32:194-225.
6. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998;147:718-721.
7. Persson I, Weiderpass E, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement therapy. Cancer Causes Control. 1999;10:253-260.
8. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and breast cancer with a favorable pathology. JAMA. 1999;281:2091-2097.
9. Schairer C, Gall M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91:264-270.
10. Laidfaw IJ, Clarke RB, Howell A, et al. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 1995;136:164-171.
11. Hargreaves DF, Knox F, Swindell R, Potten CS, Bundred NJ. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer. 1998;78:945-949.
12. Poutanen M, Isomaa V, Peltoketo H, Vihko R. Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol. 1995;55:525-532.
13. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332:1589-1593.
14. Greendale GA, James MK, Espeland MA, Barrett-Connor E, for the PEPI Investigators. Can we measure prior postmenopausal estrogen/progestin use? Am J Epidemiol. 1997;146:763-770.
15. Brinton LA, Hoover RN, Szklo M, et al. Menopausal estrogen use and risk of breast cancer. Cancer. 1981;47:2517-2522.